Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA) announced that founder Howard Berman, Ph.D., has stepped down as Executive Chairman and from the Board, and that Mark H. Pavao has been appointed as an independent director. The move follows a CEO transition begun in November 2024 that established Arun Swaminathan, Ph.D., as CEO. The company highlighted Pavao’s >30 years of commercial experience and said COYA 302 is approaching an important Phase 2B ALSTARS data readout as the company advances toward potential commercialization.
ReAlta Life Sciences (NASDAQ:AVIR) appointed Howard Berman, Ph.D. as Chairman and CEO and Kia Motesharei, Ph.D. as President and COO on March 24, 2026.
The hires add capital markets, deal-making, and late-stage clinical development experience as ReAlta advances pegtarazimod into late-stage trials for HIE and other indications.
Coya Therapeutics (NASDAQ: COYA) highlighted a peer‑reviewed study showing peripheral immune dysregulation in frontotemporal dementia (FTD). Blood from 27 FTD patients and 25 controls showed significantly reduced Treg suppressive function (p<0.05) and elevated pro‑inflammatory mediators including TNFα and multiple chemokines (p<0.05–0.01).
Previously reported investigator data of low‑dose IL‑2 plus CTLA‑4 Ig showed increased Treg number/function within two weeks, no cognitive decline over 22 weeks, and favorable tolerability.
Coya Therapeutics (NASDAQ: COYA) reported FY2025 results and a corporate update highlighting clinical and financial progress. Key milestones include IND acceptance for COYA 302 in FTD, ALSTARS Phase 2 launch with ~25 U.S./Canada sites, a U.S. patent for an RTU IL-2 formulation, and cash of $46.8M with financing extending runway into 2H 2027.
FY2025 revenue included $7.9M collaboration revenue and $6.7M license revenue; net loss was $21.2M.
Coya Therapeutics (NASDAQ: COYA) will host a live webinar on February 17, 2026 at 3:00 p.m. ET / 12:00 p.m. PT titled “Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress.”
The event will review ALS biology, recent treatment advances, and patient needs, highlight Coya’s immunotherapy combination COYA 302, and provide an overview of the ALSTARS Phase 2 clinical trial design and enrollment. Fred Grossman, D.O., FAPA, will moderate with experts Stanley Appel, M.D., and James Berry, M.D., MPH. Pre-registration is open, attendees may submit written Q&A, and a recording will be posted to the company website.
Coya Therapeutics (Nasdaq: COYA) entered a definitive securities purchase agreement to sell 2,522,727 shares of common stock at $4.40 per share in a private placement for gross proceeds of approximately $11.1 million, expected to close on or about January 30, 2026.
Investors are Dr. Reddy’s Laboratories ($10.0 million) and Greenlight Capital ($1.1 million). Proceeds will fund tech transfer and scale-up manufacturing for low-dose IL-2 to support commercial readiness of COYA 302. The company will file a resale registration statement with the SEC within 45 days of closing.
Coya Therapeutics (NASDAQ: COYA) issued a letter outlining 2026 priorities focused on advancing COYA 302 in ALS and FTD and progressing COYA 303 in Alzheimer’s disease. The company has initiated the ALSTARS Phase 2 ALS trial with active dosing and U.S. and Canadian sites, and targets full enrollment in H2 2026 with a topline readout in Q1 2027. Coya reported $46.8 million cash as of December 31, 2025, no debt, non-dilutive funding of $8.4 million from Dr. Reddy’s, and a cash runway into H2 2027. Additional translational datasets and a Phase 2a FTD study initiation are planned in 2026.
Coya Therapeutics (NASDAQ: COYA) reported results from a 9-patient, investigator-initiated open-label study of low-dose IL-2 plus CTLA4-Ig in frontotemporal dementia over 22 weeks of dosing. The study observed statistically significant increases in regulatory T-cell (Treg) numbers and suppressive function beginning at two weeks and sustained through week 22. Cognitive measures remained stable: MoCA (baseline 13.5, week 22 14) and CDR-FTLD (baseline 4.8, week 22 5.5) showed no meaningful decline. Safety was tolerable with no serious adverse events and injection-site erythema in 33.3% of participants. Company commented on advancing COYA 302 to a controlled Phase 2 trial.
Coya Therapeutics (NASDAQ: COYA) announced that the U.S. FDA has accepted its IND for COYA 302 to treat frontotemporal dementia (FTD) on January 5, 2026. FTD affects about 60,000 Americans, has an average onset age of 58 and average survival of 7.5 years. The company positions COYA 302 to enhance regulatory T cell (Treg) anti-inflammatory function as a disease‑modifying approach for sporadic FTD. Coya also expects to announce topline results soon from an investigator‑initiated open‑label study evaluating low‑dose IL‑2 and CTLA4‑Ig in mild‑to‑moderate FTD.
Coya Therapeutics (NASDAQ: COYA) announced that Health Canada accepted the Clinical Trial Application for COYA 302 on December 23, 2025, allowing activation of Canadian clinical sites for the ALSTARS phase 2 placebo‑controlled trial in amyotrophic lateral sclerosis (ALS).
The CTA acceptance permits patient enrollment at Canadian ALS centers, expanding recruitment alongside ongoing U.S. sites and enabling broader site activation and patient access for the study.